Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 163   

Articles published

BMY 67.40 +0.90 (1.35%)
price chart
Stock Report Bristol-Myers Squibb Co (NYSE:BMY)
[Business Wire] Bristol-Myers Squibb Co (NYSE:BMY)(TREND ANALYSIS) announced important next steps in the evolution of the company's R&D organization, including plans to expand its presence within hubs of scientific excellence and innovation with the ...
Bristol-Myers Squibb to shift research jobs  Centre Daily Times
Future Costliest Drug Classes: Bristol-Myers Squibb Co & Merck Cancer Meds ...
The approach uses the body's defenses to fight tumors. Recently approved immune-oncology drugs include Bristol-Myers and Squibb Co.'s (NYSE:BMY) CTLA4 targeting antibody Yervoy (ipilimumab) and PD-1 inhibitor Opdivo (nivolumab), and Merck & Co., ...
Piper Jaffray Rating Update on Bristol-Myers Squibb Company (NYSE:BMY)
Piper Jaffray initiates coverage on Bristol-Myers Squibb Company (NYSE:BMY). The shares have now been rated Underperform by the stock experts at the ratings house.
Healthcare Stocks in Concerns- Bristol-Myers Squibb Company (NYSE:BMY ...  StreetWise Report
Company Shares of Bristol-Myers Squibb Company Rally 1.11%  Insider Trading Report
Bristol-Myers Squibb a Top Socially Responsible Dividend Stock With 2.2 ...
Bristol-Myers Squibb Co. (NYSE: BMY) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ”DividendRank” statistics including a strong 2.2% yield, as well as being recognized by ...
Bristol-Myers Squibb Co. (NYSE:BMY) Officially Ready to Launch Opdivo in ...
Large Outflow of Money Witnessed in Bristol-Myers Squibb Company  Insider Trading Report
Why Bristol-Myers Squibb Co.'s Stock Could Sink
Bristol-Myers Squibb's share price has been going through the roof due to the company's emergence as a leader in the field of immuno-oncology.
Cancer Immunotherapy Movers: Bristol-Myers Squibb Co, Merck & Co, Novartis ...
He expects significant improvement in the response rates demonstrated by newly approved immune checkpoint inhibitors, which include Bristol-Myers and Squibb Co's (NYSE:BMY) CTLA4 targeting antibody Yervoy (ipilimumab) and PD-1 inhibitor Opdivo ...
Piper Jaffray Initiates Bristol-Myers Squibb With Underperform
Analysts at Piper Jaffray initiated coverage on Bristol-Myers Squibb Co (NYSE: BMY) with a Underperform rating. The target price for Bristol-Myers Squibb is set to $60.
European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab ...  MarketWatch
Bristol-Myers Squibb Is An Overvalued Company In Quite An Expensive Sector ...  Seeking Alpha
Shares of Bristol-Myers Squibb Company (NYSE:BMY) Sees Large Outflow of ...
Shares of Bristol-Myers Squibb Company (NYSE:BMY) traded 0.07 points or 0.11% higher at $65.77.The total intraday money flow for the counter came in at a disappointing $(-34.17) million.
Zacks Rating on Bristol-Myers Squibb Company  American Trade Journal
Bristol-Myers Squibb Company (BMY) - Market Digest  AVAFIN
Bristol-Myers Squibb Co (BMY): The P/E Multiple Is Too High
Bristol-Myers Squibb Co (NYSE:BMY) stock has been exceptionally well-rewarded by investors who are cheering on the company's ability to bring new immunotherapy drugs in the market.
Bristol Myers Squibb Co (BMY) Files Form 4 Insider Selling : Joseph C ...  Insider Trading Report
Bristol-Myers Priced for a Miracle Cure  Wall Street Journal
Bristol-Myers Squibb Demonstrates Commitment to Hematology and Advancing ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the presentation of clinical research from its hematology portfolio at the 20th Congress of the European Hematology Association (EHA) in Vienna, Austria ...
Bristol-Myers Squibb reports presentation of hematology data at EHA  RTT News
Bristol-Myers Squibb reports presentatio ...  The FINANCIAL